Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 4.6%

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) traded down 4.6% during trading on Wednesday . The stock traded as low as $23.02 and last traded at $23.02. 52,063 shares were traded during trading, a decline of 63% from the average session volume of 141,196 shares. The stock had previously closed at $24.14.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. Stifel Nicolaus assumed coverage on shares of Dianthus Therapeutics in a report on Thursday, February 15th. They set a “buy” rating and a $44.00 target price on the stock. Jefferies Financial Group increased their price target on shares of Dianthus Therapeutics from $22.00 to $39.00 and gave the company a “buy” rating in a research report on Friday, March 22nd. Wedbush increased their price target on shares of Dianthus Therapeutics from $24.00 to $33.00 and gave the company an “outperform” rating in a research report on Friday, March 22nd. Finally, Raymond James increased their price target on shares of Dianthus Therapeutics from $34.00 to $51.00 and gave the company an “outperform” rating in a research report on Thursday. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $42.40.

Dianthus Therapeutics Trading Down 1.2 %

The company’s 50-day simple moving average is $25.83 and its two-hundred day simple moving average is $17.16.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings results on Thursday, March 21st. The company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.11) by $0.40. The company had revenue of $0.46 million for the quarter, compared to analysts’ expectations of $0.73 million. As a group, equities research analysts expect that Dianthus Therapeutics, Inc. will post -1.92 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Tower Research Capital LLC TRC purchased a new position in shares of Dianthus Therapeutics during the 4th quarter worth approximately $25,000. Citigroup Inc. purchased a new position in shares of Dianthus Therapeutics during the 3rd quarter worth approximately $53,000. Dimensional Fund Advisors LP purchased a new position in shares of Dianthus Therapeutics during the 4th quarter worth approximately $153,000. Northern Trust Corp purchased a new position in shares of Dianthus Therapeutics during the 4th quarter worth approximately $159,000. Finally, Acadian Asset Management LLC purchased a new position in shares of Dianthus Therapeutics during the 3rd quarter worth approximately $303,000. Hedge funds and other institutional investors own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.